How does CSL N's PE Ratio compare to its peers?

CSL N is expensive based on its Price-To-Earnings Ratio (45.3x) compared to the peer average (22x).

How does CSL N's PE Ratio compare vs other companies in the Global Biotechs Industry?

CSL N is expensive based on its Price-To-Earnings Ratio (45.3x) compared to the Global Biotechs industry average (34.5x).

What is CSL N's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate CSL N's Price-To-Earnings Fair Ratio for valuation analysis.

What is the Fair Price of CSL N when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

CSL N (MX$3635.42) is trading above our estimate of [[fair value]] (MX$2664.2)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

CSL (BMV:CSL N) - Stock Price, News & Analysis

CSL N Stock Overview

Researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. More details

CSL N fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	3/6
Past Performance	2/6
Financial Health	4/6
Dividends	0/6

Rewards

Earnings are forecast to grow 17.87% per year

Risk Analysis

Shares are highly illiquid

Has a high level of debt

CSL Limited Competitors

Regeneron Pharmaceuticals

NasdaqGS:REGN

US$81.0b

Amgen

NasdaqGS:AMGN

US$150.5b

AbbVie

NYSE:ABBV

US$320.1b

Celltrion

KOSE:A068270

₩36.7t

Price History & Performance

Summary of all time highs, changes and price drops for CSL
Historical stock prices
Current Share Price	AU$3,635.42
52 Week High	AU$3,635.42
52 Week Low	AU$3,635.42
Beta	0.20
11 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	-15.46%
5 Year Change	n/a
Change since IPO	27.33%

Recent updates

Shareholder Returns

	CSL N	MX Biotechs	MX Market
7D	0%	0%	0%
1Y	n/a	0%	0%

Return vs Industry: Insufficient data to determine how CSL N performed against the MX Biotechs industry.

Return vs Market: Insufficient data to determine how CSL N performed against the MX Market.

Price Volatility

Is CSL N's price volatile compared to industry and market?
CSL N volatility
CSL N Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Stable Share Price: CSL N has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine CSL N's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1916	30,000	Paul McKenzie	www.csl.com.au

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants.

CSL Limited Fundamentals Summary

How do CSL's earnings and revenue compare to its market cap?
CSL N fundamental statistics
Market cap	Mex$1.73t
Earnings (TTM)	Mex$38.12b
Revenue (TTM)	Mex$210.68b

45.3x

P/E Ratio

8.2x

P/S Ratio

Is CSL N overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CSL N income statement (TTM)
Revenue	US$11.70b
Cost of Revenue	US$5.56b
Gross Profit	US$6.15b
Other Expenses	US$4.03b
Earnings	US$2.12b

Last Reported Earnings

Dec 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	4.39
Gross Margin	52.52%
Net Profit Margin	18.09%
Debt/Equity Ratio	59.7%

How did CSL N perform over the long term?

See historical performance and comparison

Dividends

1.1%

Current Dividend Yield

51%

Payout Ratio

CSL N Stock Overview

Rewards

Risk Analysis

CSL Limited Competitors

NasdaqGS:REGN

US$81.0b

NasdaqGS:AMGN

US$150.5b

NYSE:ABBV

US$320.1b

KOSE:A068270

₩36.7t

Price History & Performance

Recent News & Updates

CSL Vifor and Travere Therapeutics Announces Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain

CSL Limited to Report First Half, 2025 Results on Feb 11, 2025

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee

Recent updates

CSL Vifor and Travere Therapeutics Announces Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain

CSL Limited to Report First Half, 2025 Results on Feb 11, 2025

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee

CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024

CSL Announces Top-Line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I (Human)

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster

CSL Limited to Report Fiscal Year 2024 Results on Jul 30, 2024

CSL Behring's HEMGENIX (Etranacogene Dezaparvovec-Drlb) Demonstrates At Three Years Post-T Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults

Health Canada Authorizes Csl's Hemgenix(R) (Etranacogene Dezaparvovec) as First Gene Therapy for Hemophilia B

CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024

CSL Seqirus Announces Data from Three Studies Supporting the Clinical, Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines

CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources

Arcturus Therapeutics Holdings Inc. and Csl Seqirus Announce European Medicines Agency Validates Marketing Authorization Application for Arct-154 Vaccine to Prevent Covid-19

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

CSL Limited to Report Fiscal Year 2023 Results on Aug 15, 2023

CSL Limited Announces Interim Dividend, Payable on 5 April 2023

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited to Report First Half, 2023 Results on Feb 14, 2023

SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases

CSL Limited Announces Management Changes

CSL Limited Announces Chief Executive Officer Changes

CSL Limited Announces FDA Approval of First Gene Therapy for Adults with Hemophilia B

Independent Non Executive Director recently bought Mex$939k worth of stock

CSL Limited Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates

Non-Independent Non-Executive Director recently sold Mex$87m worth of stock

Upcoming dividend of US$1.18 per share

CSL Limited Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE)

Full year 2022 earnings released: EPS: US$4.81 (vs US$5.22 in FY 2021)

CSL Limited Announces Final Dividend for the Period Ended June 30, 2022, Payable on 6 September 2022